A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.

The present invention relates to glucoamylase variants having improved thermostability. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

The present disclosure concerns recombinant yeast host cell for saccharification of a biomass. The recombinant yeast host cell has a genetic modification for expressing a heterologous polypeptide having glucoamylase activity (Penicillum oxalicum glucoamylase). In some embodiments, the heterologous polypeptide can comprise a signal sequence. The present disclosure also concerns a process for saccharification of a biomass using the recombinant yeast host cell as well as a process for fermenting the saccharified biomass into a fermentation product.

Embodiments of the disclosure include particular amyloglucosidase (AMG) compositions formulated as a nutriceutical or medicinal food, for example. The AMG compositions are formulated at a specific dosage and/or are lacking in one or more toxins or have substantially reduced levels of toxin, such as deoxynivalenol (vomit toxin). The AMG compositions are provided to individuals in need thereof, such as an individual with or at risk for congenital sucrase isomaltase syndrome, functional bowel disorders, small bowel bacterial overgrowth, protein-calorie malnutrition (marasmus), radiochemotherapy-induced mucositis and/or short-gut syndrome.

The present invention relates to a hybrid polypeptide having alpha-amylase activity, selected from a first polypeptide sequence comprising a catalytic core, and a second polypeptide sequence comprising a carbohydrate binding module (CBM), wherein (a) the catalytic core is selected from a polypeptide having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to amino acids 20 to 494 of SEQ ID NO: 1 or amino acids 20 to 496 of SEQ ID NO: 1; and (b) the CBM is selected from a polypeptide having at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, and catalytic domains.

Embodiments of the disclosure include particular amyloglucosidase (AMG) compositions formulated as a nutriceutical or medicinal food, for example. The AMG compositions are formulated at a specific dosage and/or are lacking in one or more toxins or have substantially reduced levels of toxin, such as deoxynivalenol (vomit toxin). The AMG compositions are provided to individuals in need thereof, such as an individual with or at risk for congenital sucrase isomaltase syndrome, functional bowel disorders, small bowel bacterial overgrowth, protein-calorie malnutrition (marasmus), radiochemotherapy-induced mucositis and/or short-gut syndrome.

The present invention relates to glucoamylase variants having improved thermostability. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

The invention provides an animal feed composition comprising plant material from a transgenic plant or plant part expressing a recombinant thermotolerant -amylase. The invention further provides methods of improving feed utilization and decreasing liver abscesses. Also provided are methods of producing a steam flaked corn product, and the steam flaked corn product so produced. The invention provides an animal feed composition comprising plant material from a transgenic plant or plant part expressing a recombinant thermotolerant -amylase. The invention further provides methods of improving feed utilization and decreasing liver abscesses. Also provided are methods of producing a steam flaked corn product, and the steam flaked corn product so produced.

Disclosed herein is a method for expressing phytase in a filamentous fungus by using an optimized Escherichia coli phytase gene having a nucleotide sequence as shown in SEQ ID NO. 7 and a signal peptide having a nucleotide sequence as shown in SEQ ID NO. 12.

The present disclosure relates to alpha-amylases for use in combination with glucoamylases for improving the hydrolysis of a raw starch. The alpha-amylases can be provided in a purified form and/or can be expressed from a recombinant host cell. The present disclosure also provides a population of recombinant host cells expressing the alpha-amylases to be used in combination with recombinant host cells expressing the glucoamylases.